Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

Phase 3

SINOVAC BIOTECH LTD (SVA)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

12 competitors in Influenza

RHHBYRoche influenza treatment

MRNAmRNA Flu vaccine

SNYA/H1N1 pandemic influenza vaccine (non- adjuvanted)

Phase 3

BNTXInfluenza and COVID-19 Combination A

Phase 3

BNTXInvestigational COVID-19 Vaccine

Phase 2

View Full Landscape

Drug Information

Target Indication

Influenza

Clinical Trial

NCT07211152

Last updated: 1/29/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SVA

SINOVAC BIOTECH LTD

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

36-71 months old children-experimental EV71 vaccine.Phase 3

Hand, Foot and Mouth Disease

investigational 23-valent PPVPhase 3

Pneumococcal Infections

400U /0.5ml EV71 vaccinePhase 3

Hand, Foot and Mouth Disease

Investigational sIPVPhase 3

Poliomyelitis

PROVARIXPhase 3

Varicella (Chickenpox)

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts